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Abstract
Background: Interferon alpha (IFNa) therapy has been widely used in the treatment of chronic hepatitis B (CHB)
for decades. Nucleos(t)ide analogues are also increasingly used to treat CHB recently. More and more studies are
being carried out concerning the clearance or seroconversion of HBsAg, which is recognized as an ideal goal of
CHB therapy. This study conducted a meta-analysis to estimate the effect of pegylated interferon alpha
(peginterferon a, PEG-IFNa)-based therapy on HBsAg clearance or seroconversion in CHB.
Methods: All available controlled clinical trials, published from 2004 to 2010, with the following antiviral therapies
for CHB patients: PEG-IFNa combined with lamivudine (LAM), PEG-IFNa only, conventional IFNa and LAM, with a
course ≥24 weeks, were meta-analysed for HBsAg clearance and seroconversion.
Results: Fourteen trials (involving a total of 2,682 patients) were identified, including seven high-quality and seven
low-quality studies. The analysis results of the different antiviral therapies on HBsAg clearance or seroconversion
were as follows: 1. No significant difference in HBsAg clearance or seroconversion was observed between the
combination therapy group and PEG-IFNa monotherapy group [odds ratio (OR) = 1.16, 95% confidence intervals
(CI) (0.73-1.85), P = 0.54 and OR = 1.07, 95% CI (0.58-1.97), P = 0.82, respectively]; 2. HBsAg clearance and
seroconversion rates in patients with combination therapy were markedly higher than in those with LAM
monotherapy [OR = 9.41, 95% CI (1.18-74.94), P = 0.03, and OR = 12.37, 95% CI (1.60-95.44), P = 0.02, respectively];
3. There was significant difference in HBsAg clearance between the PEG-IFNa group and IFNa monotherapy group
[OR = 4.95, 95% CI (1.23-20.00), P = 0.02], but not in seroconversion [OR = 2.44, 95% CI (0.35-17.08), P = 0.37]; 4.
PEG-IFNa was superior to LAM in HBsAg seroconversion [OR = 14.59, 95% CI (1.91-111.49), P = 0.01].
Conclusions: PEG-IFNa facilitated HBsAg clearance or seroconversion in CHB patients. PEG-IFNa-based therapy was
more effective than LAM monotherapy in achieving HBsAg clearance or seroconversion for both HBeAg-positive
and HBeAg-negative CHB patients. There was no significant difference in HBsAg clearance or seroconversion
between PEG-IFNa/LAM combination therapy and PEG-IFNa monotherapy. PEG-IFNa was obviously superior to
conventional IFNa in HBsAg clearance, but not in HBsAg seroconversion. Although PEG-IFNa produced significantly
higher rates of HBsAg clearance and seroconversion, the absolute change in the proportion of HBsAg clearance
and seroconversion was low (about 3-6%). Therefore, additional interventions are needed to improve the rate of
positive outcomes.
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Antiviral therapy has been recognized as the first choice
for chronic hepatitis B (CHB) treatment and approved as
an efficient approach to ameliorating hepatic inflammation
and fibrosis, further preventing liver cirrhosis and hepato-
cellular carcinoma [1-4]. The state of hepatitis B virus
(HBV) DNA < 2,000 IU/mL and alanine aminotransferase
(ALT) normalization after treatment is a good prediction
in both HBeAg-positive and HBeAg-negative CHB [5-9].
Nevertheless, HBsAg clearance and seroconversion, char-
acterized by the loss of serum HBsAg with or without
anti-HBs antibody development, are the main markers of a
successful immunological response to HBV infection and
the closest outcome to clinical cure [10-14]. Some
researches indicated that interferon-based therapy, espe-
cially pegylated interferon alpha (peginterferon a, PEG-
IFNa), obviously outstripped nucleos(t)ide analogues in
achieving HBsAg clearance and seroconversion [15-23].
The weekly administration of PEG-IFNa is likely to
improve patients’ compliance rate, while obtains much
better pharmacokinetics [24]. Therefore, several practice
guidelines for the management of CHB have considered
PEG-IFNa as a first-line therapy for CHB patients [25,26].
However, it remains unclear whether the rate of HBsAg
clearance and seroconversion is higher in CHB patients
receiving PEG-IFNa-based therapy than in those receiving
conventional IFNa or nucleos(t)ide analogues.
In this study, we aimed to elucidate the efficacy of
PEG-IFNa-based therapy in the treatment of CHB.
Furthermore, our analysis also focused on the rates of
HBsAg clearance and seroconversion, which might ben-
efit to optimize the antiviral treatments for CHB. We
restricted the comparison groups to PEG-IFNa-based
therapy and conventional IFNa or lamivudine (LAM)
treatments due to no available controlled clinical trials
of PEG-IFNa-based therapy compared with nucleos(t)
ide analogues except LAM.
Methods
Literature retrieval and study design
Two researchers independently operated the literature
retrieval, trial selection and data extraction, reaching to
consensus by conferring with each other when discre-
pancies appeared. The researchers performed a systemic
literature retrieval using electronic databases including
PubMed (1966-2010), English medical Current Contents
(EMCC 1995-2010), China National Knowledge Infra-
structure (CNKI 1979-2010), China Hospital Knowledge
Database (CHKD 1994-2010) and the Cochrane library
clinical trials registry (Issue 3 of 4, Jul 2010). The retrie-
val was finished in November 2010. The following key-
words were used: ‘hepatitis B’, ‘peginterferon’, ‘pegylated
interferon’,a n d‘HBsAg’. In addition, a manual search
was conducted using citations in previous publications.
The included studies were divided into different groups
according to intervention treatments. The prognosis of
the patients were recorded and analysed. Data were
extracted by study methodology and defined efficacy
measures. Only data regarding the regimens in question
were extracted, while data concerning other regimens
were also reviewed, and if they were found to be of signif-
icance to our study, were noted and discussed. Separate
meta-analyses were performed for each group.
Criteria for inclusion and exclusion
The inclusion criteria were as follows: (i) study design:
controlled clinical trials; (ii) study population: CHB
patients; (iii) intervention: PEG-IFNa combined with
LAM therapy versus PEG-IFNa or LAM monotherapy,
PEG-IFNa versus IFNa or LAM monotherapy; (iv) out-
comes: HBsAg clearance or seroconversion.
The exclusion criteria were as follows: (i) study design:
non-clinical studies; (ii) study population: non-adult
population, women with pregnancy or lactation, patients
received liver transplantation, patients co-infected with
hepatitis C virus, hepatitis D virus or human immuno-
deficiency virus, patients with a history of alcohol or
drug abuse, hepatocellular carcinoma, decompensated
liver disease, serious medical or psychiatric illness; (iii)
intervention: concurrently using corticosteroid, immu-
nosuppressive agents or Chinese herbal medicine; (iv)
outcomes: not reporting any of the efficacy measures of
HBsAg clearance or seroconversion as defined by the
authors; (v) republished studies, or the full text were not
available. Our search was restricted by language; cita-
tions in languages other than English or Chinese were
not included.
Efficacy measures and definitions
HBsAg clearance was defined as the disappearance of
HBsAg from the serum. HBsAg seroconversion was
defined as HBsAg disappearance and anti-HBs antibody
appearance.
Study quality and homogeneity
Methodological quality of the included studies was
assessed according to the Jadad quality scale [27], an
established composite score evaluating randomization,
concealment and reporting of patient withdrawal and
dropout rates, with more than or equal to 3 scores
defined as high-quality. We performed a sensitivity ana-
lysis of quality by considering all studies to be of high-
quality. Heterogeneity was assessed for each analysis.
Statistical analyses
Quantitative meta-analyses were performed to assess dif-
ferences between PEG-IFNa-based therapy and IFNa or
LAM monotherapy groups. Statistical analysis was
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software of Review Manager (RevMan 5.0.24.0, the Nor-
dic Cochrane Center, Rigshospitalet). The odds ratios
(OR) were calculated along with their respective 95%
confidence intervals (CI) and presented for each indivi-
dual study. If a clinical trial has no subject (0%) develop-
ing the outcome of concern in either of the two
comparison groups, we just input the “zero” to the com-
puter, then it will add 0.5 to each of the four cells in the
2 × 2 table by RevMan 5.0.24.0 automatically. Statistical
heterogeneity between trials was evaluated by the chi-
square (c
2)a n dIs q u a r e( I
2) tests, with significance
being set at P < 0.10. In the absence of statistically sig-
nificant heterogeneity, the fixed-effect method was used
to combine the results. When heterogeneity was con-
firmed (P = 0.10 or lower), the random-effect method
was used. Publication bias was assessed by funnel plots.
Results
Study selection and characteristics
Our electronic and manual searches identified 518 arti-
cles. Thirty-three potentially eligible controlled clinical
trials using PEG-IFNa-based therapy for chronic HBV
infection were selected, of which nineteen were
excluded. Seventeen were duplicate publications, the
other two trials were excluded because the interventions
contained different adefovir dipivoxil-based therapy and
could not be analyzed using meta-analysis for the
marked heterogeneity with the included trials. The flow
diagram was shown in Figure 1. Therefore, fourteen
trials involving a total of 2,682 patients were analyzed in
this study. Among these trials, five presented both
HBsAg clearance and seroconversion [16,21,22,28,29],
eight displayed HBsAg clearance [17-20,23,30-32] and
one showed HBsAg seroconversion [15]. Three trials
E n g l i s h   ( n   =   8 )           C h i n e s e   ( n   =   6 )  
1. Excluded in meta-analysis (n = 2) 
2. Same studies (n = 17) 
Studies included in meta-analysis (n = 14) 
Included studies by reading full text (n = 33) 
1. Republished studies (n = 25)   
2. Did not report HBsAg clearance or seroconversion (n = 67) 
3. Without full text (n = 7)
Studies excluded: did not meet inclusion criteria (n = 386) 
Included studies by reading titles and abstract (n = 132) 
Studies retrieved by literature search (n = 518) 
Figure 1 Literature search and data extraction.
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Page 3 of 13were conducted for long-term follow-up (average 3
years) [17,19,30], the others for 0-72 weeks
[15,16,18,20-23,28,29,31,32]. Patients from eleven trials
were treated for 48 to 60 weeks [15-20,22,28,30-32], and
the rest were treated for 24 weeks [21,23,29]. Of these
studies, seven were high-quality and seven were low-
quality (Jadad scores of 3-5 and Jadad scores < 3,
respectively). All studies were published as full publica-
tions, with eight in English [15-19,28,30,31] and six in
Chinese [20-23,29,32]. Four studies used sequential ther-
apy [18,19,29,32], and six studies used concurrent ther-
apy [15-17,28,30,31] [Tables 1 and 2].
HBsAg clearance and seroconversion in patients receiving
combination therapy or monotherapies
PEG-IFNa+LAM combination therapy vs. PEG-IFNa
monotherapy
The rates of HBsAg clearance and seroconversion were
6.8% and 3.7% in the combination therapy group, and
6.0% and 3.5% in the PEG-IFNa monotherapy group,
respectively. The fixed effect model for meta-analysis was
used according to the heterogeneity test (c
2 =4 . 0 5 ,d f=
6, P =0 . 6 7 ,I
2 =0 %a n dc
2 =1 . 2 9 ,d f=3 ,P =0 . 7 3 ,I
2 =
0%, respectively). The difference between the two groups
did not show statistical significance neither in HBsAg
clearance rate [OR = 1.16, 95% CI (0.73-1.85), P =0 . 5 4 ]
nor in seroconversion rate [OR = 1.07, 95% CI (0.58-
1.97), P = 0.82] [Figure 2]. We also conducted a sensitiv-
ity analysis including high-quality studies only and
obtained the same result as the overall trials [Figure 3].
PEG-IFNa+LAM combination therapy vs. LAM monotherapy
In comparison with the LAM monotherapy, the combi-
nation therapy led to higher HBsAg clearance rates dur-
ing follow-up (2.6% vs. 0% at 24 weeks, and 6.2% vs. 0%
at 3 years, respectively). Thus, PEG-IFNa combined
with LAM therapy was significantly more effective than
LAM monotherapy in HBsAg eradication, especially in
long-term follow-ups [OR = 7.24, 95% CI (0.88-59.28),
Table 1 Characteristics of studies included in the meta-analysis
Study n Study
design
Jadad
score
Therapy
period
Follow-up
period
Therapy regimen
Lau G.K.K.
2005
814 RCT 4 48 w 24 w 1. PEG-IFNa-2a (180 ug/w) + placebo
2. PEG-IFNa-2a (180 ug/w) + LAM (100 mg/d)
3. LAM (100 mg/d)
Marcellin P.
2004
537 RCT 4 48 w 24 w 1. PEG-IFNa-2a (180 ug/w) + placebo
2. PEG-IFNa-2a (180 ug/w) + LAM (100 mg/d)
3. LAM (100 mg/d)
Marcellin P.
2009
315 RCT 4 48 w 3 y 1. PEG-IFNa-2a (180 ug/w) + placebo
2. PEG-IFNa-2a (180 ug/w) + LAM (100 mg/d)
3. LAM (100 mg/d)
Chan H.L.Y.
1
2005
100 RCT 3 52-60 w 24 w 1. PEG-IFNa-2b (1.5 ug/kg, 1/w, Wt < 65 kg; 100 ug/w, Wt ≥ 65 kg) 8 w ®
PEG-IFNa-2b + LAM 24 w ® LAM 28 w
2. LAM (100 mg/d)
Chan H.L.Y.
2
2005
95 RCT 3 52-60 w 3 y 1. PEG-IFNa-2b (1.5 ug/kg, 1/w, Wt < 65 kg; 100 ug/w, Wt ≥ 65 kg) 8 w ®
PEG-IFNa-2b + LAM 24 w ® LAM 28 w
2. LAM (100 mg/d)
Janssen HLA
2005
266 RCT 5 52 w 26 w 1. PEG-IFNa-2b (100 ug/w) + placebo
2. PEG-IFNa-2b (100 ug/w) + LAM (100 mg/d)
Buster E.H.C.J
2008
172 RCT 5 52 w 3.0 ± 0.8 y 1. PEG-IFNa-2b (100 ug/w) + placebo
2. PEG-IFNa-2b (100 ug/w) + LAM (100 mg/d)
Kaymakoglu
S. 2007
48 RCT 2 48 w 24 w 1. PEG-IFNa-2b (1.5 ug/kg, 1/w)
2. PEG-IFNa-2b (1.5 ug/kg, 1/w) + LAM (100 mg/d)
Tian YL 2007 72 RCT 2 48 w 72 w 1. PEG-IFNa-2a (180 ug/w)
2. Conventional IFNa-2a (5 MU, 1/2 d)
Huang ZL
2010
50 NRCT 1 52 w 0 1. PEG-IFNa-2a (135 ug/w) 12 w ® PEG-IFNa-2a + LAM (100 mg/d) 12 w ®
PEG-IFNa-2a 28 w
2. PEG-IFNa-2a 52 w
Cui JJ 2006 80 RCT 2 6 m 6 m 1. PEG-IFNa-2a (180 ug/w)
2. Conventional IFNa-2a (5 MU, 3/w)
Li ZQ 2010 74 NRCT 1 48 w 24 w 1. PEG-IFNa-2a (180 ug/w)
2. Conventional IFNa-2a (5 MU, 1/2 d)
Guan LJ 2006 32 RCT 2 24 w 6 m 1. PEG-IFNa-2a (180 ug/w)
2. Conventional IFNa-2b (5 MU, 1/2 d)
Shi XF 2006 27 NRCT 1 6 m 0 1. PEG-IFNa-2a (135-180 ug/w) + placebo
2. PEG-IFNa-2a (135-180 ug/w) + LAM (100 mg/d) 3 m ® PEG-IFNa-2a 3 m
PEG-IFNa-2a: pegylated interferon alpha-2a; LAM: lamivudine; RCT: randomized controlled trial; NRCT: nonrandomized controlled trial; d: days; w: weeks; m:
months; y: years.
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Study Inclusion criteria Exclusion criteria
Lau G.K.K.
2005
1. Adults 1. Treatment within 6 m
2. HBsAg positive for > 6 m and HBeAg positive 2. HIV infection, hepatitis C or D
3. HBV DNA > 500 000 copies/ml 3. Decompensated liver disease
4. Evidence of inflammation on biopsy and 1 ULN < ALT < 10 ULN 4. Serious medical or psychiatric illness
5. Alcohol or drug use within 1 y
6. Neutrophils < 1500/mm
3, platelets < 90 000/mm
3,o r
creatinine > 1.5 ULN
Marcellin P.
2004
1. Adults 1. Treatment within 6 m
2. HBsAg positive for > 6 m and HBeAg negative 2. HIV infection, hepatitis C or D
3. HBV DNA > 100 000 copies/ml 3. Decompensated liver disease
4. Evidence of inflammation on biopsy and 1 UNL < ALT < 10 ULN 4. Serious medical or psychiatric illness
5. Alcohol or drug use within 1 y
6. Neutrophils < 1500/mm
3, platelets < 90 000/mm
3,o r
creatinine > 1.5 ULN
Marcellin P.
2009
1. Adults 1. Treatment within 6 m
2. HBsAg positive for > 6 m and HBeAg negative 2. HIV infection, hepatitis C or D
3. HBV DNA > 100 000 copies/ml 3. Decompensated liver disease
4. Evidence of inflammation on biopsy and 1 ULN < ALT < 10 ULN 4. Serious medical or psychiatric illness
5. Alcohol or drug use within 1 y
6. Neutrophils < 1500/mm
3, platelets < 90 000/mm
3,o r
creatinine > 1.5 ULN
Chan H.L.Y.
1
2005
1. 18-65 years old 1. Decompensated liver disease or a history of interferon or
antiviral agent use
2. HBsAg positive for > 6 m and HBeAg positive 2. HIV infection, hepatitis C or D
3. HBV DNA > 500 000 copies/ml 3. History of hepatocellular carcinoma
4. 1.3 ULN < ALT < 5 ULN 4. Other causes of liver disease
5. Serious medical or psychiatric illness
6. Concurrent use of corticosteroid or immunosuppressive
agents
7. Pregnancy
Chan H.L.Y.
2
2005
1. 18-65 years old 1. Decompensated liver disease or a history of interferon or
antiviral agent use
2. HBsAg positive for > 6 m and HBeAg positive 2. HIV infection, hepatitis C or D
3. HBV DNA > 500 000 copies/ml 3. History of hepatocellular carcinoma
4. 1.3 ULN < ALT < 5 ULN 4. Other causes of liver disease
5. Serious medical or psychiatric illness
6. Concurrent use of corticosteroid or immunosuppressive
agents
7. Pregnancy
Janssen HLA
2005
1. ≥ 16 years old 1. Antiviral or immunosuppressive therapy within 6 m
2. HBsAg positive for > 6 m and HBeAg positive on two occasions
within 8 w of randomization
2. HIV infection, hepatitis C or D
3. Evidence of inflammation by two measurements of ALT > 2 ULN
within 8 w of randomization
3. Advanced liver disease or carcinoma
4. Serious medical or psychiatric illness, or uncontrolled thyroid
disease
5. Substance abuse within 2 y
6. Pregnancy or inadequate contraception
7. Leucocytes ≤ 3000/mm
3, neutrophils ≤ 1800/mm
3,o r
platelets ≤ 100 000/mm
3
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Buster E.H.C.
J 2008
1. ≥ 16 years old 1. Antiviral or immunosuppressive therapy within 6 m
2. HBsAg positive for > 6 m and HBeAg positive on two occasions
within 8 w of randomization
2. HIV infection, hepatitis C or D
3. Evidence of inflammation by two measurements of ALT > 2 ULN
within 8 w of randomization
3. Advanced liver disease or carcinoma
4. Serious medical or psychiatric illness, or uncontrolled thyroid
disease
5. Substance abuse within 2 y
6. Pregnancy or inadequate contraception
7. Leucocytes ≤ 3000/mm
3, neutrophils ≤ 1800/mm
3,o r
platelets ≤ 100 000/mm
3
Kaymakoglu
S. 2007
1. ≥ 18 years old 1. Other cause of chronic liver disease
2. HBsAg positive for > 6 m, HBeAg negativity on two occasions in
the past 3 m, ALT > 1.3 ULN on two occasions during the
preceding 3 m
2. Received immunosuppressive or antiviral treatment in the
previous 6 m
3. HBV DNA positivity (lower limit of detection [LLD], 4 pg/ml) 3. Exhibited hepatocellular carcinoma
4. Compensated liver disease with histological evidence of chronic
hepatitis
Tian YL 2007 1. 18-60 years old 1. Pregnancy or lactation
2. Without using antiviral or immunosuppressive therapy within 6 m 2. Serum albumin < 3.5 g/L; PT prolong ≥ 4 s; serum bilirubin >
34 μmol/L; pretreatment neutrophils < 1.5 × 10
9/L; Platelets <
90 × 10
9/L; hemoglobin (male) < 125 g/L, (female) < 115 g/L
3. HBV DNA > 500 000 copies/ml 3. Hepatitis A, C, D or E
4. At least two occasions of ALT > 100-500 U/L within 6 m before
treatment, and at least one occasion within 35 d before treatment,
interval time ≥ 14 d
4. Serious medical or psychiatric illness
5. Autoimmune liver disease or alcoholic hepatitis
Huang ZL
2010
1. HBsAg positive for > 6 m and HBeAg positive 1. Leucocytes ≤ 3.0 × 10
9/L, platelets ≤ 75 × 10
9/L
2. HBV DNA > 100 000 copies/ml 2. Pregnancy or lactation
3. Without using antiviral therapy within 6 m and ALT > 2 ULN
within 3 m
3. HIV infection, other viral hepatitis
4. Malignant tumor
5. Serious medical or psychiatric illness, or uncontrolled thyroid
disease, diabetes mellitus, autoimmune disease et al
Cui JJ 2006 1. HBsAg positive for > 6 m, HBeAg positive, HBV DNA > 100 000
copies/ml
Not reported
2. 2 ULN < ALT < 10 ULN
3. Without other viral hepatitis or HIV infection
4. Without using antiviral or immunosuppressive therapy within 6 m
5. Neutrophils > 15 × 10
9/L, Platelets > 90 × 10
9/L
6. Without serious medical, psychiatric illness or decompensated
liver disease
Li ZQ 2010 1. HBsAg positive for > 6 m, HBeAg positive Not reported
2. ALT > 80 U/L, HBV DNA > 10
4IU/ml
3. Without other viral hepatitis
4. Without using antiviral or immunosuppressive therapy within 6 m
Guan LJ
2006
1. Course of disease is 2-8 y Not reported
2. 18-55 years old
3. Pretreatment 1.5 ULN < ALT < 10 ULN, HBsAg positive, HBeAg
negative, HBV DNA > 100 000 copies/ml
4. Without other viral hepatitis
5. Without using antiviral therapy pretreatment and without
contraindication of antiviral therapy
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Page 6 of 13P = 0.07, and OR = 9.41, 95% CI (1.18-74.94), P =0 . 0 3 ,
respectively]. The fixed effect model for meta-analysis
was used according to the heterogeneity test (c
2 =0 . 3 7 ,
df = 1, P = 0.54, I
2 = 0% and c
2 = 0.60, df = 1, P = 0.44,
I
2 = 0%, respectively).
Similarly, HBsAg seroconversion rate was 2.4% in the
combination therapy group and 0% in the LAM mono-
therapy group. Heterogeneities were assessed and no
concern was found (c
2 = 0.19, df = 1, P = 0.67, I
2 =
0%), thus allowing the use of a fixed effect model for
meta-analysis. The difference reached statistical
significance [OR = 12.37, 95% CI (1.60-95.44), P =0 . 0 2 ]
[Figure 4].
PEG-IFNa monotherapy vs. IFNa monotherapy
The rates of both HBsAg clearance and HBsAg serocon-
version in the PEG-IFNa monotherapy group (7.6% and
4.1%) exceeded the IFNa monotherapy group (0.8% and
1.4%). The fixed effect model for meta-analysis was used
according to the heterogeneity test (c
2 =0 . 4 3 ,d f=3 ,P
= 0.93, I
2 =0 %a n dc
2 =0 . 0 2 ,d f=1 ,P =0 . 8 9 ,I
2 =0 % ,
respectively). Significant difference in HBsAg clearance
rates was observed between the two groups [OR = 4.95,
Table 2 Patient selection criteria of studies included in the meta-analysis (Continued)
Shi XF 2006 1. 16-60 years old 1. Decompensated liver disease
2. Without using antiviral therapy within 6 m or virological relapse
or YMDD mutation after more than 1 y LAM treatment
2. Serious medical or psychiatric illness
3. HBsAg positive, HBeAg positive 3. Neutrophils < 1500/mm
3, Platelets ≤ 70 000/mm
3
4. HBV DNA > 100 000 copies/ml, or relapse (increase 2 log 10
copies/ml)
4. Hepatitis A, C, D or E
5. Serum total bilirubin < 40 umol/L 5. alcohol or drugs abuse within 1 y
6. PEG-IFNa-2a monotherapy group 2 ULN < ALT < 10 ULN; PEG-
IFNa-2a combination with LAM group ALT < 10 ULN
HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e antigen; HBV: hepatitis B virus; ALT: alanine aminotransferase; ULN: upper limit of normal; HIV: human
immunodeficiency virus; PEG-IFNa-2a: pegylated interferon alpha-2a; LAM: lamivudine; d: days; m: months; y: years.
Study or Subgroup
1.1.1 HBsAg clearance
Buster E.H.C.J2008
Huang ZL 2010
Janssen HLA2005
Kaymakoglu S.2007
Marcellin P.2004
Marcellin P.2009
Shi XF 2006
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 4.05, df = 6 (P = 0.67); I² = 0%
Test for overall effect: Z = 0.62 (P = 0.54)
1.1.2 HBsAg seroconversion
Janssen HLA2005
Lau G.K.K.2005
Marcellin P.2004
Shi XF 2006
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 1.29, df = 3 (P = 0.73); I² = 0%
Test for overall effect: Z = 0.22 (P = 0.82)
Events
12
1
9
1
5
9
2
39
9
8
3
2
22
Total
81
24
130
29
179
114
13
570
130
271
179
13
593
Events
7
0
9
2
7
9
1
35
7
8
5
1
21
Total
91
26
136
19
177
116
14
579
136
271
177
14
598
Weight
17.3%
1.4%
25.2%
7.2%
21.1%
25.3%
2.5%
100.0%
32.0%
39.0%
24.9%
4.1%
100.0%
M-H, Fixed, 95% CI
2.09 [0.78, 5.59]
3.38 [0.13, 87.11]
1.05 [0.40, 2.73]
0.30 [0.03, 3.61]
0.70 [0.22, 2.24]
1.02 [0.39, 2.67]
2.36 [0.19, 29.71]
1.16 [0.73, 1.85]
1.37 [0.50, 3.80]
1.00 [0.37, 2.70]
0.59 [0.14, 2.49]
2.36 [0.19, 29.71]
1.07 [0.58, 1.97]
PEG-IFNĮ+LAM(COM) PEG-IFNĮ Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours PEG-IFNĮ Favours COM
Figure 2 Analysis of HBsAg clearance and HBsAg seroconversion between PEG-IFNa+LAM combination therapy and PEG-IFNa
monotherapy (overall trials).
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2.1.1 HBsAg clearance
Buster E.H.C.J2008
Janssen HLA2005
Marcellin P.2004
Marcellin P.2009
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 2.14, df = 3 (P = 0.54); I² = 0%
Test for overall effect: Z = 0.85 (P = 0.40)
2.1.2 HBsAg seroconversion
Janssen HLA2005
Lau G.K.K.2005
Marcellin P.2004
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.89, df = 2 (P = 0.64); I² = 0%
Test for overall effect: Z = 0.05 (P = 0.96)
Events
12
9
5
9
35
3
8
9
20
Total
81
130
179
114
504
179
271
130
580
Events
7
9
7
7
30
5
8
7
20
Total
91
136
177
116
520
177
271
136
584
Weight
20.8%
30.3%
25.3%
23.6%
100.0%
25.9%
40.7%
33.4%
100.0%
M-H, Fixed, 95% CI
2.09 [0.78, 5.59]
1.05 [0.40, 2.73]
0.70 [0.22, 2.24]
1.33 [0.48, 3.71]
1.24 [0.75, 2.06]
0.59 [0.14, 2.49]
1.00 [0.37, 2.70]
1.37 [0.50, 3.80]
1.02 [0.54, 1.91]
COM PEG-IFNĮ Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours PEG-IFNĮ Favours COM
Figure 3 Analysis of HBsAg clearance and HBsAg seroconversion between PEG-IFNa+LAM combination therapy and PEG-IFNa
monotherapy (high-quality studies).
Study or Subgroup
3.1.1 HBsAg clearance by 24w follow-up
Chan H.L.Y. 2005
Marcellin P.2004
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.37, df = 1 (P = 0.54); I² = 0%
Test for overall effect: Z = 1.84 (P = 0.07)
3.1.2 HBsAg clearance by 3y follow-up
Chan H.L.Y.2005
Marcellin P.2009
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.60, df = 1 (P = 0.44); I² = 0%
Test for overall effect: Z = 2.12 (P = 0.03)
3.1.3 HBsAg seroconversion
Lau G.K.K.2005
Marcellin P.2004
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.19, df = 1 (P = 0.67); I² = 0%
Test for overall effect: Z = 2.41 (P = 0.02)
Events
1
5
6
1
9
10
8
3
11
Total
50
179
229
48
114
162
271
179
450
Events
0
0
0
0
0
0
0
0
0
Total
50
181
231
47
85
132
272
181
453
Weight
50.2%
49.8%
100.0%
48.3%
51.7%
100.0%
49.8%
50.2%
100.0%
M-H, Fixed, 95% CI
3.06 [0.12, 76.95]
11.44 [0.63, 208.46]
7.24 [0.88, 59.28]
3.00 [0.12, 75.52]
15.40 [0.88, 268.36]
9.41 [1.18, 74.94]
17.58 [1.01, 306.12]
7.20 [0.37, 140.37]
12.37 [1.60, 95.44]
COML A M Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours LAM Favours COM
Figure 4 Analysis of HBsAg clearance and HBsAg seroconversion between PEG-IFNa+LAM combination therapy and LAM
monotherapy.
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Page 8 of 1395% CI (1.23-20.00), P = 0.02], but not in seroconver-
sion rates [OR = 2.44, 95% CI (0.35-17.08), P =0 . 3 7 ]
[Figure 5].
PEG-IFNa monotherapy vs. LAM monotherapy
HBsAg seroconversion rate was 2.9% in PEG-IFNa
monotherapy group and 0% in LAM monotherapy
group. The fixed effect model for meta-analysis was
used according to the heterogeneity test (c
2 = 0.04, df =
1, P =0 . 8 4 ,I
2 = 0%). The difference between the two
groups reached statistical significance [OR = 14.59, 95%
CI (1.91-111.49), P = 0.01] [Figure 6].
Publication bias
An assessment of publication bias was conducted using
funnel plots. Evidences of publication bias based on the
funnel plots were found in comparison of combination
therapy with PEG-IFNa monotherapy on HBsAg clear-
ance and HBsAg seroconversion only among high-
Study or Subgroup
4.1.1 HBsAg clearance
Cui JJ 2006
Guan LJ 2006
Li ZQ 2010
Tian YL2007
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.43, df = 3 (P = 0.93); I² = 0%
Test for overall effect: Z = 2.25 (P = 0.02)
4.1.2 HBsAg seroconversion
Cui JJ 2006
Li ZQ 2010
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.02, df = 1 (P = 0.89); I² = 0%
Test for overall effect: Z = 0.90 (P = 0.37)
Events
3
1
2
3
9
2
1
3
Total
35
16
38
30
119
35
38
73
Events
1
0
0
0
1
1
0
1
Total
37
16
36
42
131
37
36
73
Weight
40.5%
20.8%
21.9%
16.9%
100.0%
65.0%
35.0%
100.0%
M-H, Fixed, 95% CI
3.38 [0.33, 34.09]
3.19 [0.12, 84.43]
5.00 [0.23, 107.80]
10.82 [0.54, 217.67]
4.95 [1.23, 20.00]
2.18 [0.19, 25.20]
2.92 [0.12, 74.03]
2.44 [0.35, 17.08]
PEG-IFNĮ IFNĮ Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours IFNĮ Favours PEG-IFNĮ
Figure 5 Analysis of HBsAg clearance and HBsAg seroconversion between PEG-IFNa and IFNa monotherapy.
Study or Subgroup
5.1.1 HBsAg seroconversion
Lau G.K.K.2005
Marcellin P.2004
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.04, df = 1 (P = 0.84); I² = 0%
Test for overall effect: Z = 2.58 (P = 0.010)
Events
8
5
13
Total
271
177
448
Events
0
0
0
Total
272
181
453
Weight
50.2%
49.8%
100.0%
M-H, Fixed, 95% CI
17.58 [1.01, 306.12]
11.57 [0.64, 210.88]
14.59 [1.91, 111.49]
PEG-IFNĮ LAM Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours LAM Favours PEG-IFNĮ
Figure 6 Analysis of HBsAg seroconversion between PEG-IFNa and LAM monotherapy.
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Page 9 of 13quality studies [Figure 7]. There was no apparent publi-
cation bias in the other comparison groups.
Discussion
Currently there are two kinds of antiviral agents for the
treatment of CHB patients, interferon (conventional or
pegylated interferon) and nucleos(t)ide analogues (lami-
vudine, telbivudine, adefovir, entecavir, and tenofovir). It
has been documented that interferon is more efficient
than nucleos(t)ide analogues on HBeAg clearance and
HBeAg seroconversion. However, the use of interferon
was restricted because of the inconvenience of injection
and risk of adverse reactions. Nucleos(t)ide analogues
were more convenient to use and strongly suppressed
HBV DNA replication. However, nucleos(t)ide analo-
gues had the disadvantages of developing resistance and
there is no established course of treatment. Combina-
tion therapy with interferon and nucleos(t)ide analogues
was prompted in order to enhance the therapeutic
efficacy.
HBsAg clearance or seroconversion, which might pre-
dict intrahepatic covalently closed circular DNA
(cccDNA) reduction, is the ultimate outcome of antiviral
therapy. However, there are not sufficient studies
involved in this objective. Compared with any single
study, meta-analysis has increased power for statistical
tests, and increased precision for confidence intervals,
because the conclusions often reflect a broad spectrum
of patients and study characteristics, and the results are
more generalizable than a single study. Our study is the
first to analyse PEG-IFNa-based therapy for CHB treat-
ment focusing on HBsAg clearance or seroconversion,
pooling data from all pertinent clinical-controlled trials
into meta-analysis. This analysis is to achieve evidence-
based conclusions on the matter, to resolve the contro-
versy over the selection of antiviral regimens, and to be
further referred to by future clinical investigations.
In this analysis, we found that PEG-IFNa monotherapy
and combination with PEG-IFNa and LAM obtained
comparable efficacies, achieving similar rates of HBsAg
Subgroups
HBsAg loss
HBsAg seroconversion
0.01 0.1 1 10 100
0
0.2
0.4
0.6
0.8
1
OR
SE(log[OR])
Figure 7 Assessment of publication bias for PEG-IFNa+LAM combination therapy versus PEG-IFNa monotherapy on HBsAg clearance
and HBsAg seroconversion (high-quality studies).
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Page 10 of 13clearance and seroconversion (P = 0.54 and 0.82 respec-
tively) [15-17,28-32]. We also set up subgroups for meta-
analysis according to follow-up terms, but no significant
difference was obtained. Thus, the addition of LAM to
PEG-IFNa regimen could not promote the clinical cure in
defined course of treatment but brought heavy financial
burden to patients. Up to date, there was seldom reports
of randomized controlled clinical trials based on combina-
tion therapy with PEG-IFNa and other nucleos(t)ide ana-
logues. Paola Piccolo et al [33] performed a multicenter
randomized controlled trial, in which a total of 60 patients
were included and efficacies of PEG-IFNa monotherapy
and combination therapy with PEG-IFNa and adefovir
dipivoxil were compared. Only one patient (3.3%) in the
combination therapy group obtained HBsAg clearance
during 24 w follow-up. The combination of PEG-IFNa
with more potential nucleos(t)ide analogues such as ente-
cavir or tenofovir needs to be further investigated in large,
randomized studies. Nucleos(t)ide analogues typically
demand to be continued indefinitely to maintain viral sup-
pression, without a clearly defined endpoint for stopping
treatment. This approach increases the risk of antiviral
resistance, and the safety of long-term therapy with
nucleos(t)ide analogues also needs to be explored.
Higher rates of HBsAg clearance and seroconversion
were observed in patients receiving the combination
regimen as compared with those receiving LAM mono-
therapy [15-19]. Increasing HBsAg loss rate was only
obtained by long-term follow-up [17,19]. Patients treated
with PEG-IFNa monotherapy achieved higher rate of
HBsAg seroconversion as compared with those treated
with LAM monotherapy [15,16]. The difference in
HBsAg clearance or seroconversion rates might relate to
antiviral mechanisms of the agents. There are two
mechanisms of interferon action: (i) direct antiviral
effect by suppressing synthesis of viral DNA and by acti-
vating antiviral enzymes; and (ii) magnification of the
cellular immune response against hepatocytes infected
with HBV [34]. PEG-IFNa-based therapy exerts persis-
tently an immunomodulatory activity to produce antibo-
dies to HBV antigens and sustained virological response.
Otherwise, nucleos(t)ide analogues, such as LAM, sup-
presses HBV replication by inhibiting the reverse tran-
scriptase activity of HBV polymerase. Only a few
patients sustained the response and HBsAg loss after 6
months of treatment discontinuation [35,36]. The same
conclusions were drawn from comparisons between
PEG-IFNa and adefovir dipivoxil or entecavir [37-39].
Complementary activity of immunoregulation and sus-
tained suppression of HBV replication in CHB patients
can be achieved by combination of PEG-IFNa and
nucleos(t)ide analogues, which can initiate specific
immune response to bring about HBsAg elimination
and seroconversion.
C l e a r a n c er a t eo fH B s A gw a ss i g n i f i c a n t l yh i g h e ri n
patients receiving PEG-IFNa monotherapy than in those
receiving conventional IFNa monotherapy [20-23],
which might attribute to their different pharmacoki-
netics. Conventional IFNa was administered once every
other day, and it reached peak concentration rapidly in
the blood and got lower at intervals. PEG-IFNa was
used once per week, with its effective blood concentra-
tion persisting for a week [24]. Currently, the updated
therapeutic guidelines on management of CHB suggest
that PEG-IFNa should be administered instead of con-
ventional IFNa to improve antiviral response.
Three studies providing 3-year follow-up data were
included for the analysis of HBsAg clearance rate in
our study. Higher rate of HBsAg clearance was
observed in patients with the combination therapy as
compared with those using LAM monotherapy (P =
0.03), but no significant difference was observed after
short-term follow-up investigation (P = 0.07). The sus-
tained long-term efficacy of PEG-IFNa-based therapy
was reflected by increased proportion of patients
achieving HBsAg clearance during follow-up
[17,30,40,41]. It may attribute to the effect of PEG-
IFNa since HBsAg clearance was rarely obtained in
patients treated with lamivudine, adefovir, entecavir or
tenofovir [42-44]. It also indicated that long-term fol-
low-up is necessary to achieve evidence of optimized
antiviral strategy.
Our study contains several limitations. Firstly,
although no difference was found between the high-
quality studies and the overall trials in the comparison
of the combination therapy group and PEG-IFNa
monotherapy group, the low-quality studies in our ana-
lysis, especially those in Chinese publications, which
lacked randomization, may weaken our conclusions.
Secondly, while this study focused on PEG-IFNa and
LAM combination therapy, combinations of PEG-IFNa
with other potent antiviral agents need to be further
explored, which was limited by deficient data currently
available. Finally, the absence of adequate controlled
trials precluded our analysis on the subsets of PEG-
IFNa-2a or 2b, as well as HBeAg positive or negative
CHB patients.
Conclusions
PEG-IFNa facilitated HBsAg clearance or seroconver-
sion in CHB patients. PEG-IFNa-based therapy was
more effective than LAM monotherapy in achieving
HBsAg clearance or seroconversion for both HBeAg-
positive and HBeAg-negative CHB patients. There was
no significant difference in HBsAg clearance or serocon-
version between the combination therapy and PEG-
IFNa monotherapy. PEG-IFNa was obviously superior
to conventional IFNa in HBsAg clearance, but not in
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Page 11 of 13HBsAg seroconversion. Although PEG-IFNa produced
significantly higher rates of HBsAg clearance and sero-
conversion, the absolute change in the proportion of
HBsAg clearance and seroconversion was low (about 3-
6%). Therefore, additional interventions are needed to
improve positive outcomes.
List of Abbreviations
IFNα: interferon alpha; PEG-IFNα: pegylated interferon alpha, peginterferon α;
LAM: lamivudine; CHB: chronic hepatitis B; HBsAg: hepatitis B surface
antigen; HBeAg: hepatitis B e antigen; HBV: hepatitis B virus; cccDNA:
covalently closed circular DNA; ALT: alanine aminotransferase; ULN: upper
limit of normal; HIV: human immunodeficiency virus; OR: odds ratio; CI:
confidence intervals; χ
2: chi-square; I
2: I square; RCT: randomized controlled
trial; NRCT: nonrandomized controlled trial; d: days; w: weeks; m: months; y:
years.
Acknowledgements
We thank Prof. Qing-bao Tian (Public Health College of Hebei Medical
University, China) and Prof. Jun Yu (Institute of Digestive Disease and
Department of Medicine and Therapeutics, The Chinese University of Hong
Kong, Hong Kong) for their advices on this study.
Author details
1Department of Traditional and Western Medical Hepatology, Third Hospital
of Hebei Medical University, Shijiazhuang, China.
2Department of Infectious
diseases, Nanjing 81 Hospital, Nanjing 210002, China.
Authors’ contributions
YN designed the research; WL and WR operated the literature retrieval, trial
selection and data extraction; WL, MW, LK and YZ analyzed data; WL, MW,
LK, WR and YZ wrote the paper. All authors read and approved the final
manuscript.
Competing interests
The authors report no conflicts of interest. The authors alone are responsible
for the content and writing of the paper.
Received: 5 January 2011 Accepted: 9 June 2011 Published: 9 June 2011
References
1. Wilkins T, Zimmerman D, Schade RR: Hepatitis B: Diagnosis and
Treatment. Am Fam Physician 2010, 81:965-972.
2. Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ: Current
treatment indications and strategies in chronic hepatitis B virus
infection. World J Gastroenterol 2008, 14:6902-6910.
3. Liaw YF, Chu CM: Hepatitis B virus infection. Lancet 2009, 373:582-592.
4. Zoulim F, Perrillo R: Hepatitis B: Reflections on the current approach to
antiviral therapy. J Hepatol 2008, 48:S2-S19.
5. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF: Long-
term outcome after spontaneous HBeAg seroconversion in patients
with chronic hepatitis B. Hepatology 2002, 35:1522-1527.
6. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L,
Häussinger D: Long-term follow-up of HBeAg-positive patients treated
with interferon alfa for chronic hepatitis B. N Engl J Med 1996,
334:1422-1427.
7. Hadziyannis SJ, Vassilopoulos D: Hepatitis B e antigen-negative chronic
hepatitis B. Hepatology 2001, 34:617-624.
8. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM,
Bonino F: Outcome of anti-HBe positive chronic hepatitis B in alpha-
interferon treated and untreated patients: a long term cohort study.
J Hepatol 2002, 36:263-270.
9. Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E,
Morabito A, Colombo M: Long-term suppression of hepatitis B e antigen-
negative chronic hepatitis B by 24-month interferon therapy. Hepatology
2003, 37:756-763.
10. Lok AS, McMahon BJ: Chronic hepatitis B: update of recommendations.
Hepatology 2004, 39:857-861.
11. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A,
Paumgartner G, Pietrangelo A, Rodés J, Rosenberg W, Valla D, EASL Jury:
EASL International Consensus Conference on Hepatitis B, 13-14
September, 2002, Geneva, Switzerland: consensus statement (long
version). J Hepatol 2003, 39:S3-S25.
12. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45:507-539.
13. Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG,
Solinas A, Almasio P, Hadziyannis S, Degos F, de Moura MC, Krogsgaard K,
Pantalena M, Realdi G, Corrocher R, Schalm SW: Delayed clearance of
serum HBsAg in compensated cirrhosis B: relation to interferon alpha
therapy and disease prognosis. Am J Gastroenterol 1998, 93:896-900.
14. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF: Interferon
therapy in HBeAg positive chronic hepatitis reduces progression to
cirrhosis and hepatocellular carcinoma. J Hepatol 2007, 46:45-52.
15. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G,
Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R,
McCloud P, Pluck N, Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis
B Study Group: Peginterferon alfa-2a, Lamivudine, and the combination
for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682-2695.
16. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM,
Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY,
Button P, Pluck N, Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis
B Study Group: Peginterferon alfa-2a alone, Lamivudine alone, and the
two in combination in patients with HBeAg-negative chronic hepatitis B.
N Engl J Med 2004, 351:1206-1217.
17. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R,
Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S, Peginterferon alfa-2a in
HBeAg-negative Chronic Hepatitis B Study Group: Sustained Response of
Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with
Peginterferon Alfa-2a. Gastroenterology 2009, 136:2169-2179.
18. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, Chan FK,
Hung LC, Lee YT, Tam JS, Lam CW, Sung JJ: Randomized, Controlled Trial
of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated
Interferon-2b and Lamivudine with Lamivudine Alone. Ann Intern Med
2005, 142:240-250.
19. Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ: Long-Term
Follow-Up of Peginterferon and Lamivudine Combination Treatment in
HBeAg-Positive Chronic Hepatitis B. Hepatology 2005, 41:1357-1364.
20. Tian YL, Zhao W, Shen L, Liu W, Chang JB, Fang ZX, Yin WW, Wang L,
Sun XB, Yang YJ: Pegylated interferon alpha 2a in treating chronic
hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2006, 14:806-810.
21. Cui JJ, Fan P, Jiang XL, Xu C, He Q, Zhou BP: Efficacy and safety of
peginterferon alfa-2a treatment in patients with HBeAg-positive chronic
hepatitis B. Chinese J Exp Clin Virol 2006, 20:331-333.
22. Li ZQ, Sun CY, Wu SH, Yu ZJ, Jiang HQ: Evaluation of Efficacy of Peg-
interferonα-2a Therapy in patients with HBeAg Positive Chronic
Hepatitis B. Journal of Medical Forum 2010, 31:51-53.
23. Guan LJ, Fan RS, Chen JF: Pegylated interferon in treating HBeAg
negative chronic hepatitis B patients. Clinical Medical Journal of China
2006, 13:959.
24. Lau GK: HBeAg-positive chronic hepatitis B: why do I treat my patients
with pegylated interferon. Liver International 2009, 29:125-129.
25. Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009,
50:661-662.
26. European Association for the Study of the Liver: EASL Clinical Practice
Guidelines: Management of chronic hepatitis B. J Hepatol 2009,
50:227-242.
27. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ,
McQuay HJ: Assessing the quality of reports of randomized clinical trials:
is blinding necessary? Control Clin Trials 1996, 17:1-12.
28. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US,
Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG,
Zondervan P, Hansen B, Schalm SW, HBV 99-01 Study Group; Rotterdam
Foundation for Liver Research: Pegylated interferon alfa-2b alone or in
combination with lamivudine for HBeAg-positive chronic hepatitis B: a
randomised trial. Lancet 2005, 365:123-129.
29. Shi XF: The Primary Clinical Study of Peginterferon Alfa-2a in the
Treatment the Patients with HBeAg-Positive Chronic Hepatitis B and
with Drug Fast to Lamivudine. CNKI: CDMD , 1.2006.176314.
30. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM,
Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ,
Li et al. BMC Infectious Diseases 2011, 11:165
http://www.biomedcentral.com/1471-2334/11/165
Page 12 of 13Hansen BE, Janssen HL: Sustained HBeAg and HBsAg Loss after Long-
term Follow-up of HBeAg-Positive Patients Treated With Peginterferon
α-2b. Gastroenterology 2008, 135:459-467.
31. Kaymakoglu S, Oguz D, Gur G, Gurel S, Tankurt E, Ersöz G, Ozenirler S,
Kalayci C, Poturoglu S, Cakaloglu Y, Okten A: Pegylated Interferon Alfa-2b
Monotherapy and Pegylated Interferon Alfa-2b plus Lamivudine
Combination Therapy for Patients with Hepatitis B Virus E Antigen-
Negative Chronic Hepatitis B. Antimicrob Agents Chemother 2007,
51:3020-3022.
32. Huang ZL, Zhao ZX, Deng H, Zhang YF, Lu CR, Gao ZL: A pilot study of
peginterferon alfa-2a combined with short-term lamivudine therapy in
HBeAg-positive chronic hepatitis B patients. Zhonghua Gan Zang Bing Za
Zhi 2010, 18:419-422.
33. Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, Nosotti L,
Mari T, De Santis A, Ponti ML, Sorbello O, Iacomi F, Angelico M: A
randomized controlled trail of pegylated interferon-alpha 2a plus
adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
Antiviral Therapy 2009, 14:1165-1174.
34. Marcellin P, Lada O, Asselah T: Treatment of chronic hepatitis B with the
combination of pegylated interferon with lamivudine. Hepatology
Research 2007, 37:S55-S61.
35. Shouval D, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, Han S,
Kaymakoglu S, Tamez R, Yang J, Tenney D, Brett-Smith H: Relapse of
hepatitis B in HBeAg-negative chronic hepatitis B patients who
discontinued successful entecavir treatment: the case for continuous
antiviral therapy. J Hepatol 2009, 50:289-295.
36. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL: Nucleos(t)ide
analogues only induce temporary hepatitis B e antigen seroconversion
in most patients with chronic hepatitis B. Gastroenterology 2010,
139:491-498.
37. Tang SB, Ke CZ, Kang J, Li D, Chen Y: Investigation of PEG-IFNα-2a
treatment of chronic hepatitis B patients who failed to lamivudine
therapy. J Cl in Hepatol 2007, 10:311-312.
38. Hou J, Sun J, Xie Q, Li X, Zhang J, Wang Y, Wang H, Jak YL, Chen S, Jia J,
Sheng J, Chan H, Wang J, Li M, Jiang M, Popescu M, Sung J: A prospective,
randomized study of efficacy and safety of peginterferon alfa-2a versus
adefovir dipivoxil in treating lamivudine-resistant HBeAg-positive CHB. J
Hepatol 2009, 50:S330.
39. Chen XF, Chen XP, Huang J, Chen W-L, Chen R: Comparison of
peginterferon alfa-2a versus entecavir in patients with HBeAg-positive
chronic hepatitis B with mildly elevated alanine aminotransferase levels.
J Hepatol 2009, 50:S328.
40. Marcellin P, Piratvisuth T, Brunetto M, Bonino F, Popescu M, Farci P,
Yurdaydin C, Wu J, Lau GKK: Virological and biochemical response in
patients with HBeAg negative chronic hepatitis B treated with
peginterferon alfa-2a (40 kd) with or without lamivudine: results of
4-year follow-up. J Hepatol 2008, 48:S48.
41. Marcellin P, Piratvisuth T, Brunetto M, Bonino F, Lau GKK, Farci P,
Yurdaydin C, Gurel S, Wu J, Popescu M: Increasing rates of HBsAg
clearance and seroconversion in patients with HBeAg-negative disease
treated with peginterferon alfa-2a ± lamivudine: results of 5-year post-
treatment follow up. J Hepatol 2009, 50:S336.
42. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M,
Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G,
Brosgart CL, Adefovir Dipivoxil 438 Study Group: Long-term therapy with
adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med
2005, 352:2673-2681.
43. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z,
DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L, BEHoLD
AI463027 Study Group: Entecavir versus lamivudine for patients with
HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011-1020.
44. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z,
Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K,
Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK,
Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F:
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic
hepatitis B. N Engl J Med 2008, 359:2442-2455.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/11/165/prepub
doi:10.1186/1471-2334-11-165
Cite this article as: Li et al.: Peginterferon alpha-based therapy for
chronic hepatitis B focusing on HBsAg clearance or seroconversion: a
meta-analysis of controlled clinical trials. BMC Infectious Diseases 2011
11:165.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Li et al. BMC Infectious Diseases 2011, 11:165
http://www.biomedcentral.com/1471-2334/11/165
Page 13 of 13